MAPS Public Benefit Corporation (MAPS PBC) has announced that the final participant in the second Phase 3 trial of psychedelic-assisted therapy, A Multi-Site Phase 3 Study of MDMA-Assisted Therapy for …
FOR IMMEDIATE RELEASE: May 9, 2022 The second, confirmatory Phase 3 trial of MDMA-assisted therapy for PTSD is now fully enrolled at 13 sites in the United States and Israel Completion of enrollment on …
On March 22, 2022, all study sites have met the criteria to provide treatment in the cross-over extension study for MAPS-sponsored Phase 3 trials of MDMA-assisted therapy for posttraumatic stress disorder …
On February 3, our Phase 3 study site for MDMA-assisted psychotherapy for PTSD in Tel Hashomer, Israel, officially opened for phone screenings and informed consent visits. Led by Principal Investigator …
Our second Phase 3 clinical trial of MDMA-assisted therapy for PTSD is well underway, with enrollment of more than two-thirds of the participants needed to complete the study. We have also begun our long …
We are currently seeking research volunteers for our second Phase 3 clinical trial of MDMA-assisted therapy for PTSD. We’ve already accrued about 57 of the 100 subjects needed so potential volunteers …
We are currently seeking research volunteers for our second Phase 3 clinical trial of MDMA-assisted therapy for PTSD. Volunteers must have PTSD and live in an area close to a study site. People of color …
We are currently seeking research volunteers for our second Phase 3 clinical trial of MDMA-assisted therapy for PTSD. Volunteers must have PTSD and live in an area close to a study site. Volunteers will …
We are currently seeking research volunteers for our second Phase 3 clinical trial of MDMA-assisted therapy for PTSD. Volunteers must have PTSD and live in an area close to a study site. Volunteers will …
We are currently seeking research volunteers for our second Phase 3 clinical trial of MDMA-assisted therapy for PTSD. Volunteers will help contribute to scientific knowledge and will help us better understand …
On June 11, 2021, the first participant in Be’er Ya’akov (Merhavim), Israel, was enrolled in our randomized, double-blind, placebo-controlled, multi-site Phase 3 study of the efficacy and safety of …
